SM
Sumitomo Pharma Co., Ltd.
SMDPY · OTC
$11.00 +5.26% (+$0.55)
1M +10.70%
Market Cap ¥723.9B
P/E Ratio 6.33x
Div. Yield -
ROE 36.26%
Bulios Fair Price
$8.04
26.9% downside
Current Price
$11
Undervalued Fair Value Overvalued
According to Bulios Fair Price, SMDPY is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
6/9Valuation
98 /100
Cheap EV/EBITDA 6.22x
P/S 1.50x
P/B 1.77x
Growth
0 /100
Declining Rev. growth 10.70%
FCF growth 41.96%
Book val. growth 34.67%
Profitability
76 /100
Strong Net margin 23.69%
Op. margin 10.15%
FCF margin 13.06%
Quality
71 /100
Excellent ROE 36.26%
ROA 13.53%
Asset turnover 0.57x
Debt
89 /100
Low Current ratio 1.21x
Int. coverage 13.96x
Net debt/EBITDA 0.65x
Stability
24 /100
Unstable Rev. volatility 35.35%
EPS volatility 226.80%
Profitable years 1
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about SMDPY
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Toru Kimura
Employees
4,980
Headquarters
Osaka